Abstract
Metabolic reprograming contributes to esophageal tumorigenesis. A better understanding of how esophageal cancer (EC) cells reactivate primitive signaling to retain glucose metabolism under unfavorable conditions is essential for the development of therapeutic interventions to treat EC. Current achievements in the field of EC glucose metabolism have been critically reviewed to address several fundamental questions. These include: 1) the association of abnormal glucose metabolism and EC risk; 2) alterations of genes and/or proteins that contribute to glucose oncometabolism in EC; 3) signal transduction pathways that promote EC consumption of glucose; and, 4) targeting the glycolytic element or the EC dependency on excessive glucose consumption to prevent growth of EC caused by different genomic changes.
Keywords: Tumor metabolism, glycolysis, mitochondria, altered genes, inhibitors, glucose dependence.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Glucose Oncometabolism of Esophageal Cancer
Volume: 17 Issue: 3
Author(s): Jason S. Hochwald and Jianliang Zhang
Affiliation:
Keywords: Tumor metabolism, glycolysis, mitochondria, altered genes, inhibitors, glucose dependence.
Abstract: Metabolic reprograming contributes to esophageal tumorigenesis. A better understanding of how esophageal cancer (EC) cells reactivate primitive signaling to retain glucose metabolism under unfavorable conditions is essential for the development of therapeutic interventions to treat EC. Current achievements in the field of EC glucose metabolism have been critically reviewed to address several fundamental questions. These include: 1) the association of abnormal glucose metabolism and EC risk; 2) alterations of genes and/or proteins that contribute to glucose oncometabolism in EC; 3) signal transduction pathways that promote EC consumption of glucose; and, 4) targeting the glycolytic element or the EC dependency on excessive glucose consumption to prevent growth of EC caused by different genomic changes.
Export Options
About this article
Cite this article as:
Hochwald S. Jason and Zhang Jianliang, Glucose Oncometabolism of Esophageal Cancer, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (3) . https://dx.doi.org/10.2174/1871520616666160627092716
DOI https://dx.doi.org/10.2174/1871520616666160627092716 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lentiviral-Mediated Overexpression of MicroRNA-141 Promotes Cell Proliferation and Inhibits Apoptosis in Human Esophageal Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery A New 4-phenyl-1,8-naphthyridine Derivative Affects Carcinoma Cell Proliferation by Impairing Cell Cycle Progression and Inducing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms of Epithelial Regeneration and Neovascularization During Healing of Gastric and Esophageal Ulcers
Current Medicinal Chemistry An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Protease-Activated Receptors (PARs) as Therapeutic Targets: Development of Agonists / Antagonists and Modulation of Gastrointestinal Functions
Drug Design Reviews - Online (Discontinued) Editorial (Thematic Issue: Perspectives on Strategies for Overcoming Cancer Therapy Resistance)
Current Protein & Peptide Science 31P NMR Spectroscopy of Phospholipids: From Micelles to Membranes
Current Analytical Chemistry Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Characterization of the Prostaglandin E2 Pathway in a Rat Model of Esophageal Adenocarcinoma
Current Cancer Drug Targets Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology MEK Inhibition Increases Lapatinib Sensitivity Via Modulation of FOXM1
Current Medicinal Chemistry Structurally Modified ‘Dietary Flavonoids’: Are these Viable Drug Candidates for Chemoprevention?
Current Clinical Pharmacology Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Genomic Organization and Control of the Grb7 Gene Family
Current Genomics Small-molecule Inhibitors of Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinases (TK)
Current Pharmaceutical Design Tumour Reactions to Hypoxia
Current Molecular Medicine RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets